- Home
- GBDC vs APLS Comparison
GBDC vs APLS Comparison
Compare GBDC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBDC
- APLS
- Stock Information
- Founded
- GBDC 2009
- APLS 2009
- Country
- GBDC United States
- APLS United States
- Employees
- GBDC N/A
- APLS N/A
- Industry
- GBDC Finance: Consumer Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- GBDC Finance
- APLS Health Care
- Exchange
- GBDC Nasdaq
- APLS Nasdaq
- Market Cap
- GBDC 3.7B
- APLS 3.5B
- IPO Year
- GBDC 2010
- APLS 2017
- Fundamental
- Price
- GBDC $13.48
- APLS $26.35
- Analyst Decision
- GBDC Buy
- APLS Buy
- Analyst Count
- GBDC 3
- APLS 20
- Target Price
- GBDC $15.00
- APLS $33.47
- AVG Volume (30 Days)
- GBDC 1.9M
- APLS 2.3M
- Earning Date
- GBDC 11-18-2025
- APLS 11-04-2025
- Dividend Yield
- GBDC 11.77%
- APLS N/A
- EPS Growth
- GBDC N/A
- APLS N/A
- EPS
- GBDC 1.41
- APLS N/A
- Revenue
- GBDC $877,342,000.00
- APLS $754,649,000.00
- Revenue This Year
- GBDC $23.63
- APLS $22.11
- Revenue Next Year
- GBDC N/A
- APLS N/A
- P/E Ratio
- GBDC $9.62
- APLS N/A
- Revenue Growth
- GBDC 31.97
- APLS 20.02
- 52 Week Low
- GBDC $12.68
- APLS $16.10
- 52 Week High
- GBDC $16.01
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- GBDC 32.34
- APLS 65.45
- Support Level
- GBDC $13.51
- APLS $21.07
- Resistance Level
- GBDC $13.91
- APLS $23.50
- Average True Range (ATR)
- GBDC 0.23
- APLS 0.84
- MACD
- GBDC -0.01
- APLS 0.36
- Stochastic Oscillator
- GBDC 5.06
- APLS 100.00
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.